These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35279140)

  • 1. Molecular surveillance for operationally relevant genetic polymorphisms in Plasmodium falciparum in Southern Chad, 2016-2017.
    Das S; Kérah-Hinzoumbé C; Kebféné M; Srisutham S; Nagorngar TY; Saralamba N; Vongpromek R; Khomvarn T; Sibley CH; Guérin PJ; Imwong M; Dhorda M
    Malar J; 2022 Mar; 21(1):83. PubMed ID: 35279140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar.
    Wu Y; Soe MT; Aung PL; Zhao L; Zeng W; Menezes L; Yang Z; Kyaw MP; Cui L
    Malar J; 2020 Aug; 19(1):304. PubMed ID: 32854686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes.
    Sitali L; Mwenda MC; Miller JM; Bridges DJ; Hawela MB; Hamainza B; Mudenda-Chilufya M; Chizema-Kawesha E; Daniels RF; Eisele TP; Nerland AH; Chipeta J; Lindtjorn B
    Acta Trop; 2020 Dec; 212():105704. PubMed ID: 33002448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Chad: clinical and genetic surveillance.
    Issa MS; Warsame M; Mahamat MHT; Saleh IDM; Boulotigam K; Djimrassengar H; Issa AH; Abdelkader O; Hassoumi M; Djimadoum M; Doderer-Lang C; Ndihiokubwayo JB; Rasmussen C; Menard D
    Malar J; 2023 Aug; 22(1):240. PubMed ID: 37612601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018-2019.
    Yobi DM; Kayiba NK; Mvumbi DM; Boreux R; Kabututu PZ; Situakibanza HNT; Umesumbu SE; De Mol P; Speybroeck N; Mvumbi GL; Hayette MP
    Malar J; 2021 Mar; 20(1):144. PubMed ID: 33706773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
    Otienoburu SD; Maïga-Ascofaré O; Schramm B; Jullien V; Jones JJ; Zolia YM; Houzé P; Ashley EA; Kiechel JR; Guérin PJ; Le Bras J; Houzé S
    Malar J; 2016 Sep; 15(1):452. PubMed ID: 27596849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya.
    Zhou Z; Gimnig JE; Sergent SB; Liu Y; Abong'o B; Otieno K; Chebore W; Shah MP; Williamson J; Ter Kuile FO; Hamel MJ; Kariuki S; Desai M; Samuels AM; Walker ED; Shi YP
    Malar J; 2022 Sep; 21(1):265. PubMed ID: 36100912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.
    Ljolje D; Dimbu PR; Kelley J; Goldman I; Nace D; Macaia A; Halsey ES; Ringwald P; Fortes F; Udhayakumar V; Talundzic E; Lucchi NW; Plucinski MM
    Malar J; 2018 Feb; 17(1):84. PubMed ID: 29458380
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Somé AF; Conrad MD; Kabré Z; Fofana A; Yerbanga RS; Bazié T; Neya C; Somé M; Kagambega TJ; Legac J; Garg S; Bailey JA; Ouédraogo J-B; Rosenthal PJ; Cooper RA
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0153423. PubMed ID: 38411062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.
    Ishengoma DS; Mandara CI; Francis F; Talundzic E; Lucchi NW; Ngasala B; Kabanywanyi AM; Mahende MK; Kamugisha E; Kavishe RA; Muro F; Mohamed A; Mandike R; Mkude S; Chacky F; Paxton L; Greer G; Kitojo CA; Njau R; Martin T; Venkatesan M; Warsame M; Halsey ES; Udhayakumar V
    Malar J; 2019 Mar; 18(1):88. PubMed ID: 30898164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance profile and clonality of Plasmodium falciparum parasites in Cape Verde: the 2017 malaria outbreak.
    Da Veiga Leal S; Ward D; Campino S; Benavente ED; Ibrahim A; Claret T; Isaías V; Monteiro D; Clark TG; Gonçalves L; Valdez T; da Luz Lima Mendonça M; Silveira H; Nogueira F
    Malar J; 2021 Mar; 20(1):172. PubMed ID: 33789667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018-2019.
    Khan AQ; Pernaute-Lau L; Khattak AA; Luijcx S; Aydin-Schmidt B; Hussain M; Khan TA; Mufti FU; Morris U
    Malar J; 2020 Jun; 19(1):206. PubMed ID: 32513171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan.
    Khattak AA; Venkatesan M; Jacob CG; Artimovich EM; Nadeem MF; Nighat F; Hombhanje F; Mita T; Malik SA; Plowe CV
    Malar J; 2013 Aug; 12():300. PubMed ID: 23988011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali.
    Mahamar A; Sumner KM; Levitt B; Freedman B; Traore A; Barry A; Issiaka D; Dembele AB; Kanoute MB; Attaher O; Diarra BN; Sagara I; Djimde A; Duffy PE; Fried M; Taylor SM; Dicko A
    Malar J; 2022 Feb; 21(1):39. PubMed ID: 35135546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018.
    Dentinger CM; Rakotomanga TA; Rakotondrandriana A; Rakotoarisoa A; Rason MA; Moriarty LF; Steinhardt LC; Kapesa L; Razafindrakoto J; Svigel SS; Lucchi NW; Udhayakumar V; Halsey ES; Ratsimbasoa CA
    Malar J; 2021 Nov; 20(1):432. PubMed ID: 34732201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Plasmodium falciparum drug resistance associated molecular markers in Mandla, Madhya Pradesh, India.
    Singh A; Singh MP; Ali NA; Poriya R; Rajvanshi H; Nisar S; Bhandari S; Sahu RS; Jayswar H; Mishra AK; Das A; Kaur H; Anvikar AR; Escalante AA; Lal AA; Bharti PK
    Malar J; 2023 Dec; 22(1):375. PubMed ID: 38072967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
    Venkatesan M; Gadalla NB; Stepniewska K; Dahal P; Nsanzabana C; Moriera C; Price RN; Mårtensson A; Rosenthal PJ; Dorsey G; Sutherland CJ; Guérin P; Davis TME; Ménard D; Adam I; Ademowo G; Arze C; Baliraine FN; Berens-Riha N; Björkman A; Borrmann S; Checchi F; Desai M; Dhorda M; Djimdé AA; El-Sayed BB; Eshetu T; Eyase F; Falade C; Faucher JF; Fröberg G; Grivoyannis A; Hamour S; Houzé S; Johnson J; Kamugisha E; Kariuki S; Kiechel JR; Kironde F; Kofoed PE; LeBras J; Malmberg M; Mwai L; Ngasala B; Nosten F; Nsobya SL; Nzila A; Oguike M; Otienoburu SD; Ogutu B; Ouédraogo JB; Piola P; Rombo L; Schramm B; Somé AF; Thwing J; Ursing J; Wong RPM; Zeynudin A; Zongo I; Plowe CV; Sibley CH; Asaq Molecular Marker Study Group
    Am J Trop Med Hyg; 2014 Oct; 91(4):833-843. PubMed ID: 25048375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.
    Bakari C; Mandara CI; Madebe RA; Seth MD; Ngasala B; Kamugisha E; Ahmed M; Francis F; Bushukatale S; Chiduo M; Makene T; Kabanywanyi AM; Mahende MK; Kavishe RA; Muro F; Mkude S; Mandike R; Molteni F; Chacky F; Bishanga DR; Njau RJA; Warsame M; Kabula B; Nyinondi SS; Lucchi NW; Talundzic E; Venkatesan M; Moriarty LF; Serbantez N; Kitojo C; Reaves EJ; Halsey ES; Mohamed A; Udhayakumar V; Ishengoma DS
    Malar J; 2024 Mar; 23(1):71. PubMed ID: 38461239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.
    Malmberg M; Ngasala B; Ferreira PE; Larsson E; Jovel I; Hjalmarsson A; Petzold M; Premji Z; Gil JP; Björkman A; Mårtensson A
    Malar J; 2013 Mar; 12():103. PubMed ID: 23506218
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhao W; Li X; Yang Q; Zhou L; Duan M; Pan M; Qin Y; Li X; Wang X; Zeng W; Zhao H; Sun K; Zhu W; Afrane Y; Amoah LE; Abuaku B; Duah-Quashie NO; Huang Y; Cui L; Yang Z
    Front Cell Infect Microbiol; 2022; 12():1015957. PubMed ID: 36310880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.